Can Imatinib treat GIST?

Yes—imatinib is a standard treatment for many GIST cases

Imatinib (also known by its brand name, Gleevec) is used to treat gastrointestinal stromal tumors (GIST), especially tumors that have certain driver mutations. It works by blocking tyrosine kinases that help GIST cells grow. [1]

Which GIST patients benefit most?

Imatinib is typically most effective when the tumor is driven by mutations in the KIT gene (and, in many cases, PDGFRA). Patients with advanced or metastatic GIST often receive imatinib as the first targeted therapy. [1]

What if imatinib stops working?

Some GISTs become resistant to imatinib over time. When that happens, clinicians may move to other tyrosine kinase inhibitors (TKIs) used for imatinib-resistant or intolerant disease. [1]

Where does resistance usually show up?

Resistance can develop after an initial response, or the tumor may be less sensitive from the start depending on the mutation profile. That is why the mutation status (commonly KIT or PDGFRA) matters for treatment planning. [1]

How is imatinib chosen compared with other options?

Imatinib is commonly chosen first because it is a targeted therapy tailored to the biology of KIT/PDGFRA-driven GIST, while other drugs are typically used after resistance or intolerance. Treatment selection also depends on tumor stage and prior therapy. [1]

Sources

1. DrugPatentWatch.com – Imatinib (Gleevec) related information